Medical device biocompatibility: where to begin biological safety testing
This article was originally published in SRA
Executive Summary
Nancy J Stark and Daniel E McLain explain why US companies need to reverse their thinking and carry out chemical characterisation of a material before using "the matrix" to look at tissue contact and duration.